πŸ‡ΊπŸ‡Έ FDA
Patent

US 11926625

HPK1 antagonists and uses thereof

granted A61PA61P31/12A61P35/00

Quick answer

US patent 11926625 (HPK1 antagonists and uses thereof) held by Nimbus Saturn, Inc. expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Nimbus Saturn, Inc.
Grant date
Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P31/12, A61P35/00